PL2976072T3 - Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę - Google Patents

Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę

Info

Publication number
PL2976072T3
PL2976072T3 PL14768584T PL14768584T PL2976072T3 PL 2976072 T3 PL2976072 T3 PL 2976072T3 PL 14768584 T PL14768584 T PL 14768584T PL 14768584 T PL14768584 T PL 14768584T PL 2976072 T3 PL2976072 T3 PL 2976072T3
Authority
PL
Poland
Prior art keywords
epinephrine
treatment
methods
fine particles
conditions responsive
Prior art date
Application number
PL14768584T
Other languages
English (en)
Inventor
Ousama Rachid
Keith Simons
Estelle Simons
Mutasem Rawas-Qalaji
Original Assignee
Nova Southeastern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nova Southeastern University filed Critical Nova Southeastern University
Publication of PL2976072T3 publication Critical patent/PL2976072T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
PL14768584T 2013-03-22 2014-03-24 Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę PL2976072T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361804519P 2013-03-22 2013-03-22
US201361804892P 2013-03-25 2013-03-25
EP14768584.6A EP2976072B9 (en) 2013-03-22 2014-03-24 Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
PCT/US2014/031579 WO2014153559A1 (en) 2013-03-22 2014-03-24 Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine

Publications (1)

Publication Number Publication Date
PL2976072T3 true PL2976072T3 (pl) 2021-11-22

Family

ID=51581536

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14768584T PL2976072T3 (pl) 2013-03-22 2014-03-24 Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę

Country Status (10)

Country Link
US (2) US11229613B2 (pl)
EP (2) EP3888642A1 (pl)
CA (1) CA2907770C (pl)
DK (1) DK2976072T3 (pl)
ES (1) ES2882530T3 (pl)
HR (1) HRP20211286T1 (pl)
HU (1) HUE055773T2 (pl)
PL (1) PL2976072T3 (pl)
PT (1) PT2976072T (pl)
WO (1) WO2014153559A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP3888642A1 (en) 2013-03-22 2021-10-06 Nova Southeastern University Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
AU2018329496A1 (en) 2017-09-06 2020-03-19 pHase Pharmaceuticals LLC Sublingual epinephrine tablets
BR112023018833A2 (pt) 2021-03-16 2023-12-26 Eli?Ka Ma?Kova Composições de filme oromucosal compreendendo partículas de epinefrina

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US5622716A (en) 1987-02-20 1997-04-22 Farmarc Nederland B.V. Process for preparing a retard product containing diltiazem for a single daily administration
US5223614A (en) 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
US5143731A (en) 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
JP3802555B2 (ja) 1991-12-17 2006-07-26 フイズ テクノロジーズ リミテッド 潰瘍予防及び治療組成物並びに方法
US5654003A (en) 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
JPH08502980A (ja) 1992-11-05 1996-04-02 メルク エンド カンパニー インコーポレーテッド 薬剤配送装置
US20070122465A1 (en) 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
JP2004509920A (ja) 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
US6833377B2 (en) 2001-02-05 2004-12-21 Gevys Pharmaceuticals Ltd. Composition and method for potentiating drugs
WO2003004009A1 (en) 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
EA007906B1 (ru) 2002-04-19 2007-02-27 Астион Девелопмент А/С Комбинация агониста бета-2-адренорецепторов и аминосахара и их применение для лечения иммуномодуляторных расстройств
PT1531794T (pt) * 2002-06-28 2017-09-14 Civitas Therapeutics Inc Epinefrina inalável
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
US9162005B2 (en) 2005-04-25 2015-10-20 Arch Biosurgery, Inc. Compositions for prevention of adhesions and other barrier applications
CA2611985C (en) 2005-06-17 2016-08-16 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20070202163A1 (en) * 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20150164827A1 (en) 2005-09-09 2015-06-18 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US8906392B2 (en) 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
WO2007143674A2 (en) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
US9114077B2 (en) 2006-11-17 2015-08-25 Abbvie Deutschland Gmbh & Co Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
US20090263476A1 (en) 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
EP2133414A1 (en) 2008-06-11 2009-12-16 Basf Se Uses and methods for preventing and /or treating oral malodour
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CN101669917B (zh) 2009-09-23 2013-07-24 中国人民解放军第二军医大学 一种基于“NiMS”系统的氢溴酸东莨菪碱口腔速崩微囊片
CN101841990B (zh) 2010-01-28 2012-05-30 鸿富锦精密工业（深圳）有限公司 带支撑架的电子设备
US20120322884A1 (en) * 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2853084C (en) 2011-10-21 2022-04-26 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
KR20130076015A (ko) 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP3888642A1 (en) 2013-03-22 2021-10-06 Nova Southeastern University Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
CN104666401B (zh) 2015-03-17 2019-03-05 成都乾坤动物药业股份有限公司 一种兽用中西药复方口崩微粉片及其制备方法
LT3280447T (lt) 2015-04-08 2019-05-27 Torrent Pharmaceuticals Limited Farmacinės kompozicijos
CA3116730A1 (en) 2018-10-19 2020-04-23 Nova Southeastern University Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof

Also Published As

Publication number Publication date
HRP20211286T1 (hr) 2021-12-24
PT2976072T (pt) 2021-08-12
CA2907770C (en) 2022-02-15
US20220218629A1 (en) 2022-07-14
US11229613B2 (en) 2022-01-25
EP2976072A4 (en) 2016-09-07
CA2907770A1 (en) 2014-09-25
WO2014153559A1 (en) 2014-09-25
EP2976072B1 (en) 2021-05-12
US20190125698A1 (en) 2019-05-02
EP2976072A1 (en) 2016-01-27
DK2976072T3 (da) 2021-08-16
EP2976072B9 (en) 2021-10-13
HUE055773T2 (hu) 2021-12-28
EP3888642A1 (en) 2021-10-06
ES2882530T3 (es) 2021-12-02

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
ZA201604810B (en) Surface treatment of particles and their use
HK1219975A1 (zh) 用於病毒生產的細胞系和使用方法
HK1217428A1 (zh) 取代的苯並噁唑及其使用方法
ZA201604860B (en) Surface treatment of particles and their use
HRP20170840T4 (hr) Supstituirani ksantini i metode njihove uporabe
EP2976072A4 (en) THIN PARTICLES OF EPINEPHRINE AND METHODS OF USE THEREOF FOR THE TREATMENT OF EPINEPHRINE-RELATING CONDITIONS
EP2970317A4 (en) PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
GB201320723D0 (en) Composition and methods of treatment
EP2971292A4 (en) ELECTROSPINNING DEVICE AND METHOD OF USE THEREOF
EP2968825A4 (en) GAS STABILIZED PARTICLES AND METHODS OF USE
EP2861224A4 (en) EPINHEPHRINE NANOPARTICLES, PROCESS FOR THEIR MANUFACTURE AND METHODS OF USE THEREOF FOR THE TREATMENT OF EPINEPHRINE-RESPONSIBLE DISORDERS
IL240505A0 (en) Accumulations of lanthanides and methods for their use
GB201320519D0 (en) Improvements to attachment device and method of use thereof